Skip to content
Drug Policy Watch™
LatestTracking drug policy in all 50 states and Congress, updated every morning.See all ›
Drug Policy Watch · State Brief 2026

Maine

Snapshot (structured)

Adult-use cannabis
Legal, voter approved 2016, retail sales began 2020. Sales tax rising from 10% to 14% effective January 1, 2026.
Medical cannabis
Legal, long established program (voter approved 1999, expanded 2009), regulated by the Office of Cannabis Policy.
Home grow
Legal for adults 21+, up to 3 mature plants, 12 immature plants, and unlimited seedlings, in a locked enclosed space not visible to the public; municipalities may opt out.
Intoxicating hemp / hemp THC
Sales of "potentially intoxicating hemp products" to under 21 banned and packaging rules imposed under LD 1920 (Public Law 2025 c. 416); a 14% sales tax on intoxicating hemp products is scheduled to begin January 1, 2027. Exposed to the federal hemp recriminalization effective November 12, 2026.
Psychedelics
Not decriminalized. Psilocybin decriminalization bill (LD 1034) narrowly failed final enactment in June 2025 and is dead.
Broad decriminalization
No general drug decriminalization. Drug paraphernalia (including syringes and fentanyl test strips) decriminalized since October 2021.
Harm reduction
Strong. State naloxone distribution initiative, licensed syringe service programs, fentanyl test strips legal.
Governor (party)
Janet Mills (Democrat).
Legislature control
Democratic-controlled both chambers (132nd Legislature).
Citizen ballot initiatives allowed
Yes, Maine has citizen-initiated statute and people's veto processes.
Enclosure pressure score
3/5

Cannabis

Maine voters approved adult-use cannabis in November 2016, and licensed adult-use retail sales began in October 2020. The medical cannabis program is older, dating to a 1999 ballot measure with a 2009 dispensary expansion. Both programs are administered by the Office of Cannabis Policy (OCP), a division of the Department of Administrative and Financial Services (DAFS) (formerly the Office of Marijuana Policy).

Adults 21 and older may possess up to 2.5 ounces of cannabis flower, products, and concentrate combined, and up to 5 grams of cannabis concentrate (Title 28-B, sec. 1501). Home cultivation is allowed for adults: state statute provides for cultivation at a private residence, with sources describing a limit of 3 mature plants per adult (with written permission of the property owner if not your own residence), and separate references to up to 6 mature plants, 12 immature plants, and unlimited seedlings; the discrepancy appears to reflect different readings of personal-use versus per-residence limits, and municipalities can opt out of home cultivation (Title 28-B, sec. 1502). Treat the precise plant count as something to confirm against current statute.

Market structure: As of the searches reviewed, Maine has no statutory cap on the total number of state adult-use licenses, though municipalities must opt in and may cap local establishments. Reporting indicates roughly 30 of Maine's 500-plus municipalities allow adult-use retail (about 6%), with on the order of 180 licensed retail stores operating. License types span cultivation, products manufacturing, testing, retail, and sample collection. Maine has historically been notable for NOT requiring strict vertical integration and for relatively low barriers compared with limited-license states; large multi-state operators have a smaller footprint than in many states, partly because Maine dropped its residency requirement after a legal challenge. (MSO presence and vertical-integration specifics are not fully confirmed here and should be verified.)

Taxes: Adult-use cannabis carried a 10% sales tax plus a weight-based cultivation excise tax ($335/lb flower, $94/lb trim, $1.50 per immature plant/seedling, $0.30 per seed). Medical cannabis is taxed at the general 5.5% sales rate with no excise tax. Under the FY 2026-2027 state budget signed by Governor Mills, the adult-use sales tax rises from 10% to 14% effective January 1, 2026 (a 40% increase), with a parallel 14% sales tax on intoxicating hemp products scheduled for January 1, 2027, and a new per-pound excise tax on pre-rolls ($143/lb of flower and trim in pre-rolls sold between licensees). A 10% wholesale-price-based excise was also referenced as scheduled to begin in 2026; the exact final excise structure should be confirmed against the enacted budget text.

Key 2026 actions: the tax increase (above); cannabis consumption lounge legislation (LD 1365, Rep. David Boyer) which stalled; a testing/manufacturing clarification bill (LD 1488); a proposed Cannabis Advisory Council (LD 1669); and a medical-cannabis testing/tracking and tax-dedication bill (LD 1847). See Active legislation.

Hemp

Maine treats hemp-derived intoxicating cannabinoids primarily through LD 1920, enacted June 2025 as Public Law 2025, c. 416 (an emergency measure amending Title 7, sec. 2231). It created the category "potentially intoxicating hemp product" (defined around a 0.3% intoxicating-cannabinoid threshold or a ratio of 10:1 or less nonintoxicating to intoxicating cannabinoids), banned sales to anyone under 21, and required child-resistant, tamper-evident packaging for non-beverage, non-topical products. It stopped short of fully folding intoxicating hemp into the regulated cannabis system, and reporting notes the law does not impose detailed milligram caps on adult sales. An earlier, stricter proposal (SP 783) sought per-serving and per-package THC caps; its final disposition is unconfirmed here.

A 14% sales tax on intoxicating hemp products is scheduled to begin January 1, 2027 under the enacted state budget, aligning hemp THC with the new adult-use rate.

Federal exposure: On November 12, 2025, the Continuing Appropriations and Extensions Act of 2026 (Section 781) was signed, redefining hemp to a total-THC standard (0.3% total THC dry weight, inclusive of THCA and delta-8) and capping final-form products at 0.4 mg total THC per container, with a one-year delayed effective date of November 12, 2026. Analysts estimate this will render the large majority of existing hemp-derived cannabinoid products federally unlawful. Maine intoxicating-hemp sellers face this federal deadline regardless of state law, and some Maine municipalities have moved to restrict THC products in anticipation.

Psychedelics

Maine has NOT decriminalized psychedelics and has no therapeutic-access program. LD 1034 (2025-2026), sponsored by Rep. Grayson Lookner (D-Portland), would have decriminalized possession of 1 ounce or less of psilocybin by adults 21+ without authorizing production or sales. It narrowly passed initial votes in both chambers (House 70-69, Senate 17-16) but failed final enactment in June 2025 (House 74-72 against, Senate 16-16) and was marked DEAD on June 10, 2025. This followed a similar 2024 effort that was watered down to a study commission and did not pass. The ACLU of Maine and the Reason Foundation testified in favor. No new 2026 psychedelics bill was confirmed in the searches reviewed; treat the absence of a 2026 measure as unconfirmed.

Broader drug policy

Decriminalization: Maine has not enacted broad personal-possession drug decriminalization. It did decriminalize drug paraphernalia, including syringes, pipes, and fentanyl test strips (even with drug residue), effective October 2021.

Harm reduction: Maine is comparatively strong. The Maine Naloxone Distribution Initiative (established 2019) supplies state naloxone to clinical sites, community organizations, and end users. Licensed syringe service programs operate in multiple communities (Augusta, Bangor, Calais, Ellsworth, Lewiston, Machias, Portland, Sanford, Waterville, among others), distributing clean syringes, naloxone, and fentanyl test strips. In March 2025, a bipartisan majority of the Legislature's health committee rejected a bill that would have capped the number of syringes programs could distribute, preserving Maine's more flexible needs-based model. A 2025 HIV outbreak in Penobscot County (reported 22 cases since the prior October) has heightened attention to harm reduction capacity.

Sentencing and expungement: Maine enacted a cannabis record-sealing law in 2024 that is petition-based rather than automatic. Multiple bills have been introduced to create automated sealing, including in the 2026 session; specific bill numbers were not confirmed in the searches reviewed.

Overdose and treatment policy: Maine maintains state-supported overdose prevention and recovery infrastructure tracked through the Maine Drug Data Hub. Specific 2026 treatment-funding actions were not detailed in the sources reviewed.

Political landscape

Governor: Janet Mills (Democrat), serving her second term. In 2026 she launched, then dropped, a US Senate bid; she remains governor.

Party control of the 132nd Legislature: Senate, 20 Democrats and 15 Republicans (Democratic majority). House, 75 Democrats, 73 Republicans, and 3 unenrolled (narrow Democratic majority). Democrats control both chambers, though the House margin is thin, which helps explain the single-vote swings seen on the psilocybin bill.

Key committees: Cannabis matters fall to the joint standing committee with jurisdiction over cannabis (the Veterans and Legal Affairs committee handles cannabis and elections in Maine); criminal-justice and drug-policy bills run through the Criminal Justice and Public Safety committee; harm-reduction and treatment bills through Health and Human Services. (Exact committee-of-jurisdiction assignments per bill are unconfirmed here.)

Reform champions: Rep. Grayson Lookner (D-Portland) led the psilocybin decriminalization effort. Rep. David Boyer sponsored the cannabis consumption-lounge bill and has a long record on cannabis liberalization. A legislator named Duhigg is reported to be pushing to roll back the cannabis tax increase (first name and party unconfirmed).

Named opponents: Sen. Scott Cyrway (R-Albion) is among the signatories backing the citizen initiative to repeal the adult-use cannabis market. Madison Carey is the chief petitioner associated with that repeal effort ("Mainers for a Safe and Healthy Future Inc."). On psychedelics, opposition came from members who flipped on the final enactment vote; specific named opponents are unconfirmed.

Ballot initiatives

Maine allows citizen-initiated legislation and people's veto referenda. In late 2025 a group, Mainers for a Safe and Healthy Future Inc. (chief petitioner Madison Carey; Sen. Scott Cyrway among signatories), filed and was cleared to collect signatures for "An Act to Amend the Cannabis Legalization Act and the Maine Medical Use of Cannabis Act." The measure would eliminate the commercial adult-use program (cultivation, manufacturing, retail) and repeal home cultivation, while keeping legal personal possession of up to 2.5 ounces. The campaign did NOT submit signatures by the February 2, 2026 deadline (67,682 valid signatures required), so it will not appear on the November 2026 ballot; organizers now have until June 8, 2027 to qualify for the November 2027 election. Note: Ballotpedia and some outlets label this the 2026 or 2027 initiative interchangeably as the target election shifted.

Equity and expungement

Maine does NOT operate a cannabis social-equity licensing program: there are no cannabis-specific fee waivers, reduced fees, or state funding earmarked for people disproportionately harmed by prohibition, per minority-cannabis and policy-center mapping. (A separate state Social Equity and Economic Development Program exists under the Office of Business Development, but it is not a cannabis-licensing equity track.) Record relief is petition-based under a 2024 cannabis sealing law, meaning eligible people must affirmatively file rather than receiving automatic clearance; 2026 bills to automate sealing have been introduced (numbers unconfirmed). The petition-based design tends to exclude those without legal help or awareness of eligibility.

Market and barriers

Hard numbers (verify against current OCP figures): - Adult-use sales tax: 10%, rising to 14% on January 1, 2026. - Medical sales tax: 5.5%, no excise. - Cultivation excise (weight-based): about $335/lb flower, $94/lb trim, $1.50 per immature plant/seedling, $0.30 per seed; new $143/lb pre-roll excise; a 10% wholesale-based excise also referenced for 2026 (final structure unconfirmed). - Intoxicating hemp sales tax: 14% scheduled January 1, 2027. - Application fees: reported as low as roughly $100 for small cultivators; full fee schedule in Title 28-B, sec. 207. - Residency requirement: previously required, dropped after legal challenge (no current residency mandate confirmed). - License caps: no statewide cap; municipal opt-in required and local caps allowed. - Licensees: roughly 180 adult-use retail stores reported; only about 30 municipalities (about 6%) permit adult-use retail.

Enclosure read

Maine remains one of the more open adult-use markets structurally: no statewide license cap, no forced vertical integration, no residency barrier, and comparatively low entry fees, which has supported a relatively diverse base of small operators. That openness is the main reason the score is not higher.

The pressure is rising, however, on three fronts. First, the 40% jump in the adult-use tax (10% to 14%) raises operating costs and widens the price gap with the untaxed illicit and adjacent hemp markets, squeezing small licensed retailers. Second, the federal hemp recriminalization effective November 12, 2026 plus the looming 14% state hemp tax in 2027 will fence out a whole class of independent hemp-THC sellers (gas stations, convenience stores, small CBD shops), pushing intoxicating-cannabinoid commerce toward the licensed cannabis system. Third, the citizen initiative to repeal the entire commercial market, while it missed the 2026 ballot, represents a live existential threat that could erase the market for all operators by 2027. The absence of any cannabis social-equity program and the petition-based (not automatic) expungement model mean prior-conviction populations are largely fenced out of both ownership and relief. On balance this is a moderately fenced environment with strong consolidation pressure building, hence 3/5.

What to watch next

  • November 12, 2026: federal hemp recriminalization (Section 781) takes effect; watch OCP and municipal responses.
  • January 1, 2026: adult-use sales tax rises to 14% (already in effect by mid-2026); watch for repeal/rollback bills (the Duhigg effort).
  • January 1, 2027: 14% sales tax on intoxicating hemp products begins.
  • June 8, 2027: signature deadline for the cannabis-repeal citizen initiative aimed at the November 2027 ballot; watch signature gathering and any new filing.
  • Cannabis consumption lounge legislation (LD 1365): whether it is revived after stalling.
  • 132nd Legislature Second Regular Session adjourned around April 15, 2026; the next regular session (133rd Legislature, First Regular Session) convenes in early December 2026 / January 2027 following the November 2026 elections. Confirm exact convening date.

Regulators

  • Office of Cannabis Policy (OCP), within the Department of Administrative and Financial Services (DAFS): adult-use and medical cannabis licensing, rules, and enforcement. https://www.maine.gov/dafs/ocp
  • Department of Agriculture, Conservation and Forestry: industrial hemp program oversight (Title 7, sec. 2231), with intoxicating-hemp rules now intersecting OCP and the Legislature.
  • Maine Center for Disease Control and Prevention (Maine CDC) / Department of Health and Human Services: harm reduction, naloxone distribution, syringe service program licensing, and the Maine Drug Data Hub.
  • Maine Revenue Services / DAFS: cannabis and hemp taxation.

Federal exposure (2026)

Maine is one of relatively few states exposed to every active federal lever at once, because it runs both an adult-use and a medical cannabis program and is layering new hemp taxes onto a market the federal government is about to recriminalize.

Rescheduling and 280E. Cannabis remains Schedule I by default. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 moved only FDA-approved cannabis drugs and cannabis "subject to a qualifying state-issued medical license" to Schedule III; adult-use (recreational) cannabis stays Schedule I. The practical effect for Maine is a split market. Maine's medical cannabis operators, registered under the OCP medical program, gain relief from IRC Section 280E (effective April 28, 2026), meaning they can finally deduct ordinary business expenses and their effective tax burden drops sharply. Maine's adult-use licensees get nothing from this order: they remain Schedule I, still locked out of 280E deductions, and still federally illegal. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not cover state-licensed businesses as a class beyond the narrow medical carve-out, so Maine's open, multi-license adult-use market sees no structural federal relief. A broader DEA administrative hearing on systemwide rescheduling opened June 29, 2026 and may slip to 2027; until it concludes, the medical-versus-recreational tax asymmetry is the live fact. In Maine this asymmetry is sharpened by the simultaneous state move to raise the adult-use sales tax to 14% while medical stays at 5.5% with no excise, so state and federal policy now both tilt hard toward medical and against adult-use economics. Maine's structurally open market (no statewide license cap, no forced vertical integration) means the 280E relief flows to a wide base of independent medical operators rather than to a handful of incumbents, which is a meaningful counterweight to the consolidation logic that 280E relief usually triggers in capped states.

The November 12, 2026 hemp cliff. The FY2026 agriculture appropriations rider (Sec. 781, Rep. Andy Harris R-MD) narrowed the federal definition of hemp to a total-THC standard, with a practical limit of roughly 0.4 mg total THC per container, recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026. The proposed delay (H.R. 7010) was not enacted, and the 2026 Farm Bill (H.R. 7567) keeps the ban, so there is no federal off-ramp. Practical effect in Maine: the intoxicating-hemp products now sold under LD 1920 (delta-8, THCA flower, high-dose gummies, drinks) become federally unlawful at the source on November 12, 2026, regardless of Maine's own rules. Maine had just built a state regime around these products, age-gating sales under 21, imposing packaging rules, and scheduling a 14% state hemp tax for January 1, 2027. That state tax now lands on a product category the federal government is criminalizing roughly seven weeks earlier, so Maine risks taxing a market that is collapsing at the federal level. Independent hemp retailers (convenience stores, vape shops, CBD storefronts) are the ones fenced out; the surviving demand gets pushed toward the licensed OCP cannabis system, which is exactly the enclosure dynamic the rider produces nationally.

Banking. SAFER Banking remains stalled in Congress, so Maine's cannabis operators (adult-use and medical alike) still lack reliable access to mainstream banking, card processing, and normal lending. This keeps the market cash-heavy and capital-constrained, which disadvantages small Maine operators relative to better-capitalized players and partially offsets the consolidation-resisting effect of Maine's low entry barriers, since cheap licenses do not help if banking and capital are unavailable.

Psychedelics. Psilocybin, MDMA, and ibogaine remain Schedule I federally. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review of psychedelic therapies, but no approval has issued, so there is no federal access pathway yet. In Maine, the state-level door is also closed: psilocybin decriminalization (LD 1034) narrowly died at final enactment in June 2025. Maine therefore has neither a state decriminalization nor a federal medical pathway; any near-term access would have to come through the federal FDA process, not state law.

Harm reduction. Maine is comparatively strong on harm reduction (state naloxone distribution, licensed syringe service programs, decriminalized fentanyl test strips, a needs-based syringe model the Legislature declined to cap in 2025). That strength is now exposed to the SAMHSA guidance of April 24, 2026, which bars federal funds from paying for fentanyl test strips, clean syringes, and sterile water; naloxone remains federally supported. Practical effect: Maine can keep these interventions legal under state law, but federal money can no longer underwrite the syringe-and-test-strip core of its programs, shifting that cost onto the state budget and onto local programs already stretched by events like the 2025 Penobscot County HIV outbreak. The legal status is intact; the funding base is not.

Patient access and rights

This section covers what Maine law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Maine has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Maine is not among them. The absence is the finding: a Maine patient has no enforceable right to use their medicine in a hospital today.

Broader protections: Maine protects a qualifying patient in five of the six areas. A single statute, 22 M.R.S. Section 2430-C, bars discrimination in employment, housing, and school enrollment (subsection 3), protects parental rights and custody (subsection 4), and bars denial of an organ transplant based solely on medical cannabis use (subsection 5). The one gap is a general medical-care clause: Maine's protection reaches organ transplants specifically but does not extend, in the sections reviewed, to a broad guarantee against discrimination in other medical care. A Maine patient cannot be denied a transplant listing solely for lawful medical cannabis use.

Out-of-state patients: Maine offers full access to visiting patients; a patient approved in another state may purchase directly at a Maine dispensary.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Maine has not enacted a Ryan's Law. The broader protections above are a creature of Maine law, not federal law.

Sources: Maine patient protections, 22 M.R.S. Section 2430-C.

Related reading from Drug Policy Watch: the Federal Drug Policy Brief, the Schedule III rescheduling explainer, and the 50-State Matrix.

Analysis: the enclosure read in depth

Who is fenced out, who consolidates. Maine's defining feature is an unusually open market: no statewide license cap, no residency rule, no forced vertical integration, and low entry fees. That structure has historically let small growers and independent retailers in, and it is the single biggest reason Maine does not score higher on enclosure. The 2026 federal and state moves do not dismantle that openness, but they raise the cost of operating inside it. The clearest losers are the independent intoxicating-hemp sellers, who face federal recriminalization on November 12, 2026 and a new 14% state tax in 2027; that channel is being closed and its demand funneled into the licensed OCP system. The next-most-exposed group is small adult-use operators, who are squeezed from two sides at once: a 40% state tax hike (10% to 14%) that widens the gap with illicit and hemp-adjacent product, and a federal order that hands 280E relief to the medical program but not to them. Medical operators are the relative winners of 2026: Schedule III plus 280E relief plus a 5.5% rate (versus 14% adult-use) makes the medical track materially more profitable, which could pull capital and operators toward medical and away from adult-use.

State-plus-federal interaction. The two layers now point the same direction. Federally, the April 2026 order privileges medical over recreational; at the state level, Maine's tax structure does the same. Federally, the hemp rider closes the unregulated intoxicating-cannabinoid channel; at the state level, Maine is taxing that same channel into the regulated system. The net vector is enclosure-by-funneling: demand and capital are being routed out of the cheap, open, unregulated edges (hemp shops, the gray market) and the high-tax adult-use lane, and toward the medical program and the licensed system generally. Maine's open licensing keeps that funnel from terminating in a few incumbents, but banking (still stalled under SAFER) and the capital intensity of compliance still favor better-financed players over the small operators the open structure was meant to protect.

What to watch. The repeal initiative is the existential variable; if "Mainers for a Safe and Healthy Future Inc." qualifies for November 2027, the entire commercial market (and home cultivation) is on the ballot, which would be total enclosure by abolition rather than by consolidation. Watch the broader DEA rescheduling hearing (opened June 29, 2026, may slip to 2027): if adult-use eventually reaches Schedule III, the medical-versus-recreational asymmetry collapses and the squeeze on adult-use operators eases. Watch whether Maine adjusts or delays the January 1, 2027 hemp tax once the federal recriminalization actually bites. Watch the Duhigg effort to roll back the adult-use tax increase (first name and LD unconfirmed, see https://www.yahoo.com/news/duhigg-introduce-bill-aimed-removing-200500887.html). And watch the state budget response to the SAMHSA harm-reduction funding cut.

Where commons counter-moves survive. The open structure is the commons here, and it survives 2026 largely intact: no license cap, no residency requirement, no vertical-integration mandate, low fees, and roughly 180 retail stores across a diverse operator base. Home cultivation remains legal (subject to municipal opt-out). The 280E relief, because it flows to a broad medical program rather than to capped incumbents, is distributed more widely than it would be in a limited-license state. These features keep the door open for small and new entrants even as tax and federal pressure rise. What the commons lacks is any equity scaffolding: no social-equity licensing track and only petition-based (not automatic) expungement, so prior-conviction populations remain fenced out of both ownership and relief. The enclosure score of 3/5 is justified on this balance: the structural openness is real and resists the consolidation that capped states are seeing, but the combination of a 40% tax hike, the hemp cliff, the medical-versus-recreational federal split, stalled banking, and a live repeal threat is steadily raising the floor cost of participation and tilting the field toward better-capitalized and medical-side players. Not heavily enclosed, but enclosing.

Active legislation (2026)

The list below covers significant cannabis, hemp, psychedelics, and drug-policy bills from the 132nd Legislature (2025-2026). The Second Regular Session convened January 7, 2026 with a statutory adjournment of April 15, 2026, so by mid-2026 most of these are enacted, dead, or carried over. This list is NOT exhaustive; track the full set via the links below.

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

  • (Budget, LD unconfirmed) Adult-use cannabis sales tax 10% to 14%; 14% on intoxicating hemp (Jan 1, 2027); pre-roll excise (Enacted in FY26-27 budget signed by Gov. Mills; effective Jan 1, 2026)
  • (LD unconfirmed) Bill to remove/roll back the cannabis excise tax increase (Introduced 2026)
  • (LD unconfirmed) Automated cannabis record sealing/expungement (Introduced 2026)
Bill Title/Topic Chamber Status Sponsor(s)
(Budget, LD unconfirmed) Adult-use cannabis sales tax 10% to 14%; 14% on intoxicating hemp (Jan 1, 2027); pre-roll excise Both Enacted in FY26-27 budget signed by Gov. Mills; effective Jan 1, 2026 Part of Governor's budget; specific LD/sponsor unconfirmed
LD 1920 Prohibit sales of potentially intoxicating hemp products to under 21; packaging rules Both Enacted June 2025, Public Law 2025 c. 416 Unconfirmed
LD 1034 Decriminalize possession of 1 oz or less of psilocybin for adults 21+ Both DEAD, failed final enactment June 10, 2025 Rep. Grayson Lookner (D-Portland)
LD 1365 Cannabis consumption lounges (on-premises consumption endorsement) Carried over Stalled in 2026 session Rep. David Boyer
LD 1488 Cannabis/hemp testing and manufacturing clarifications (concentrate in edibles/vapes, pre-rolls) Unconfirmed Active/advanced in 132nd; OCP-related Unconfirmed
LD 1669 Establish the Cannabis Advisory Council to advise OCP and the Legislature Unconfirmed Introduced 132nd Unconfirmed
LD 1847 Medical cannabis testing/tracking parity; dedicate part of adult-use tax to medical programs; study group Unconfirmed Introduced 132nd Unconfirmed
(LD unconfirmed) Bill to remove/roll back the cannabis excise tax increase Unconfirmed Introduced 2026 Rep. Duhigg (first name and LD unconfirmed)
(LD unconfirmed) Automated cannabis record sealing/expungement Unconfirmed Introduced 2026 Unconfirmed

Live trackers for the long tail (use these, the above is not exhaustive): - LegiScan Maine 2025-2026: https://legiscan.com/ME - Maine Legislature bill search (132nd): https://legislature.maine.gov/legislature/billsearch - Office of Cannabis Policy rules and statutes: https://www.maine.gov/dafs/ocp/adult-use/rules-statutes - Marijuana Moment state coverage: https://www.marijuanamoment.net/

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →

Sources